Suchergebnisse - "LABOTKA RICHARD"

PubPharm (11)

1

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma : a randomized Phase 2 trial

enthalten in: Blood cancer journal | 2022

von Dimopoulos, M. | Schjesvold, F. | Doronin, V. | +17

2

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Richardson, P. | Kumar, S. | Masszi, T. | +19

CommentIn: J Clin Oncol. 2021 Aug 1;39(22):2423-2425. - PMID 34111942

3

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation : The Phase III TOURMALINE-MM4 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Dimopoulos, M. | Špička, I. | Quach, H. | +17

ErratumIn: J Clin Oncol. 2022 Mar 10;40(8):919. - PMID 35255230

4

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

enthalten in: Leukemia | 2020

von Goldschmidt, H. | Dimopoulos, M. | Rajkumar, S. | +10

5

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

enthalten in: Annals of hematology | 2020

von Kaiser, M. | Beksaç, M. | Gulbrandsen, N. | +14

ErratumIn: Ann Hematol. 2021 Jan;100(1):297-302. - PMID 33106909

6

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Dimopoulos, M. | Grosicki, S. | Jędrzejczak, W. | +10

7

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Dimopoulos, M. | Gay, F. | Schjesvold, F. | +124

CommentIn: Lancet. 2019 Jan 19;393(10168):204-205. - PMID 30545778

8

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

enthalten in: British journal of clinical pharmacology | 2016

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +8

9

A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease

enthalten in: American journal of hematology | 2012

von Kutlar, A. | Ataga, K. | Reid, M. | +9

10

Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease : results of a feasibility study (PROACTIVE)

enthalten in: British journal of haematology | 2012

von Styles, L. | Wager, C. | Labotka, R. | +15